Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 7Other hematologic neoplasm 3Lymphoid 3Myeloid 2Head & Neck 2Thoracic 1Sarcoma 1Gastrointestinal 1

Conditions

Sarcoma 160Glioblastoma 86Gliosarcoma 79Brain Neoplasms 52Central Nervous System Neoplasms 47Osteosarcoma 43Astrocytoma 40Sarcoma, Ewing 39Neoplasm Metastasis 37Melanoma 35Rhabdomyosarcoma 34Neoplasms 34Ovarian Neoplasms 33Glioma 32Neuroblastoma 30Breast Neoplasms 30Oligodendroglioma 29Lymphoma 28Recurrence 27Colorectal Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Dendritic Cell Sarcoma, Interdigitating 22Stomach Neoplasms 21Lymphoma, Non-Hodgkin 21Gastrointestinal Stromal Tumors 20Carcinoma, Renal Cell 19Sarcoma, Synovial 18Pancreatic Neoplasms 18Lymphoma, Follicular 18Neurofibrosarcoma 17

Interventions

SRA737 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Fanconi Anemia × Sarcoma × Clear all
NCT02797977 2023-06-22

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Sierra Oncology LLC - a GSK company

Phase 1/2 Completed
153 enrolled
Classical hematologySarcomaThoracic

Fanconi Anemia, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡